Regulatory effect of Act1 on the BAFF pathway in B‑cell malignancy

Ge,Xiao‑Jun; Wang,Yong‑Lun; Wu,Yang Ping; Feng,Zhong‑Xin; Liu,Lan; Li,Mei  Yong; Jiang,Jun‑Yao

doi:10.3892/ol.2019.10047

Regulatory effect of Act1 on the BAFF pathway in B‑cell malignancy

Authors:
- Xiao‑Jun Ge
- Yong‑Lun Wang
- Yang Ping Wu
- Zhong‑Xin Feng
- Lan Liu
- Mei Yong Li
- Jun‑Yao Jiang
View Affiliations

Affiliations: Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou 563003, P.R. China, Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 18, 2019 https://doi.org/10.3892/ol.2019.10047
Pages: 3727-3734
Copyright: © Ge et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to ascertain whether nuclear factor (NF)‑κB Activator 1 (Act1) was involved in B cell‑activating factor (BAFF) regulation in B‑cell malignancy. The human B‑cell malignancy cell lines Raji, Daudi and BALL‑1 were cultured and the expression of BAFF receptor (BAFF‑R) mRNA and protein was analyzed by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting, respectively. NF‑κB signaling was also assessed using western blotting. Act1 silencing was performed using Act1 small interfering RNA. BAFF‑R levels were assessed using flow cytometry. It was demonstrated that BAFF‑R was upregulated in all three cell lines and RT‑qPCR, and western blotting confirmed these results. Act1 overexpression was demonstrated to induce BAFF‑R upregulation, whereas Act1 knockdown resulted in BAFF‑R downregulation. Furthermore, the NF‑κB pathway was activated by Act1 overexpression and inhibited following Act1 knockdown. The results of the present study demonstrated that Act1 can regulate BAFF via targeting NF‑κB signaling, which suggests that Act1 may be a promising therapeutic target for the treatment of B‑cell malignancy.

View Figures

View References

1	Assi LK, Wong SH, Ludwig A, Raza K, Gordon C, Salmon M, Lord JM and Scheel-Toellner D: Tumor necrosis factor alpha activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint. Arthritis Rheum. 56:1776–1786. 2007. View Article : Google Scholar : PubMed/NCBI
2	Jian S, Lin Z, Feng J, Li Y and Shen B: BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol. 597:1–5. 2008. View Article : Google Scholar : PubMed/NCBI
3	Xiao Y, Motomura S and Podack ER: APRIL (TNFSF13) regulates collagen-induced arthritis, IL-17 production and Th2 response. Eur J Immunol. 38:3450–3458. 2008. View Article : Google Scholar : PubMed/NCBI
4	Shan X, Chen L, Cao M, Xu L and Zhang S: Effects of human soluble BAFF synthesized in Escherichia coli on CD4⁺ and CD8⁺ T lymphocytes as well as NK cells in mice. Physiol Res. 55:301–307. 2006.PubMed/NCBI
5	Kothlow S, Morgenroth I, Graef Y, Schneider K, Riehl I, Staeheli P, Schneider P and Kaspers B: Unique and conserved functions of B cell-activating factor of the TNF family (BAFF) in the chicken. Int Immunol. 19:203–207. 2007. View Article : Google Scholar : PubMed/NCBI
6	Sjöstrand M, Johansson A, Aqrawi L, Olsson T, Wahren- Herlenius M and Espinosa A: The expression of BAFF is controlled by IRF transcription factors. J Immunol. 196:91–97. 2016. View Article : Google Scholar : PubMed/NCBI
7	Yang S, Li JY and Xu W: Role of BAFF/BAFF-R axis in B-cell non-Hodgkin lymphoma. Crit Rev Oncol Hematol. 91:113–122. 2014. View Article : Google Scholar : PubMed/NCBI
8	Leonardi A, Chariot A, Claudio E, Cunningham K and Siebenlist U: CIKS, a connection to Ikappa B kinase and stress-activated protein kinase. Proc Natl Acad Sci USA. 97:10494–10499. 2000. View Article : Google Scholar : PubMed/NCBI
9	Lin WW: TRAF3 regulates B cell survival and IL-6 receptor signaling. PhD dissertation. University of Iowa. doi 10.17077/etd.3jo8jplz. 2015
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Li X: Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling. Cytokine. 41:105–113. 2008. View Article : Google Scholar : PubMed/NCBI
12	Swaidani S, Bulek K, Kang Z, Liu C, Lu Y, Yin W, Aronica M and Li X: The critical role of epithelial-derived Act1 in IL-17- and IL-25-mediated pulmonary inflammation. J Immunol. 182:1631–1640. 2009. View Article : Google Scholar : PubMed/NCBI
13	Wu L, Zepp J and Li X: Function of Act1 in IL-17 family signaling and autoimmunity. Adv Exp Med Biol. 946:223–235. 2012. View Article : Google Scholar : PubMed/NCBI
14	Giltiay NV, Yi L, Allman D, Jørgensen TN and Li X: The adaptor molecule Act1 regulates BAFF responsiveness and self-reactive B cell selection during transitional B cell maturation. J Immunol. 185:99–109. 2010. View Article : Google Scholar : PubMed/NCBI
15	Hase H, Kanno Y, Kojima M, Hasegawa K, Sakurai D, Kojima H, Tsuchiya N, Tokunaga K, Masawa N, Azuma M, et al: BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood. 103:2257–2265. 2004. View Article : Google Scholar : PubMed/NCBI
16	Yang L, Zhou L, Zong X, Cao X, Ji X, Gu W and Zhang S: Characterization of the molecular structure, expression and bioactivity of the TNFSF13B (BAFF) gene of the South African clawed frog, Xenopus laevis. Int Immunopharmacol. 15:478–487. 2013. View Article : Google Scholar : PubMed/NCBI
17	Faustova M, Plestilova L, Hulejova H, Pecha O, Mann H, Putova J, Vencovsky J, Vencovsky J, Novota P and Krystufkova O: A7.11 genetic variation in promoter sequence of B-cell-activating factor of the TNF family (BAFF) in patients with idiopathic inflammatory myopathies (IIM). Ann Rheumat Dis. 72:A512013. View Article : Google Scholar
18	Thompson JS, Bixler SA, Qian F, Vora K, Scott ML, Cachero TG, Hession C, Schneider P, Sizing ID, Mullen C, et al: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science. 293:2108–2111. 2001. View Article : Google Scholar : PubMed/NCBI
19	Schneider P, Takatsuka H, Wilson A, Mackay F, Tardivel A, Lens S, Cachero TG, Finke D, Beermann F and Tschopp J: Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 194:1691–1097. 2001. View Article : Google Scholar : PubMed/NCBI
20	Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, Dobles M, Frew E and Scott ML: An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 293:2111–2114. 2001. View Article : Google Scholar : PubMed/NCBI
21	Claudio E, Brown K, Park S, Wang H and Siebenlist U: BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 3:958–965. 2002. View Article : Google Scholar : PubMed/NCBI
22	Secreto F, Manske M, Price-Troska T, Ziesmer S, Hodge LS, Ansell SM, Cerhan JR and Novak AJ: BAFF-R specific activation of TRAF6 and the PI3K-pathway in lymphoma B cells. Leuk Lymphoma. 55:1884–1892. 2014. View Article : Google Scholar : PubMed/NCBI
23	Wu H, Chen S, Liu M, Xu X, Gao K, Tian A, Ke Z, Zhang J, Zhao B and Zhang S: Molecular characterization and evolutionary analysis of horse BAFF-R, a tumor necrosis factor receptor related to B-cell survival. Int Immunopharmacol. 18:163–168. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P, Huang HQ, Lin TY, et al: Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP. Ann Hematol. 94:1865–1873. 2015. View Article : Google Scholar : PubMed/NCBI
25	Ohba H and Bakalova R: Relationships between degree of binding, cytotoxicity and cytoagglutinating activity of plant-derived agglutinins in normal lymphocytes and cultured leukemic cell lines. Cancer Chemother Pharmacol. 51:451–458. 2003.PubMed/NCBI
26	Care MA, Cocco M, Laye JP, Barnes N, Huang Y, Wang M, Barrans S, Du M, Jack A, Westhead DR, et al: SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. Nucleic Acids Res. 42:7591–7610. 2014. View Article : Google Scholar : PubMed/NCBI
27	Nicholas NS, Apollonio B and Ramsay AG: Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. Biochim Biophys Acta. 1863:471–482. 2016. View Article : Google Scholar : PubMed/NCBI
28	Lindqvist CA and Loskog AS: T regulatory cells in B-cell malignancy-tumour support or kiss of death? Immunology. 135:255–260. 2012. View Article : Google Scholar : PubMed/NCBI
29	Fidanza M, Seif AE, DeMicco A, Rolf N, Jo S, Yin B, Li Y, Barrett DM, Duque-Afonso J, Cleary ML, et al: Inhibition of precursor B-cell malignancy progression by toll-like receptor ligand-induced immune responses. Leukemia. 30:2116–2119. 2016. View Article : Google Scholar : PubMed/NCBI
30	Abolhassani H, Edwards ES, Ikinciogullari A, Jing H, Borte S, Buggert M, Du L, Matsuda-Lennikov M, Romano R, Caridha R, et al: Combined immunodeficiency and Epstein-Barr virus-induced B cell malignancy in humans with inherited CD70 deficiency. J Exp Med. 214:91–106. 2017. View Article : Google Scholar : PubMed/NCBI